Results 111 to 120 of about 184,499 (325)

mTORC2 signaling drives the development and progression of pancreatic cancer [PDF]

, 2016
mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex.
Bardeesy, Nabeel, Barry, Simon T., Driscoll, David R., Evans, T.R. Jeffry, Gay, David M., Gopinathan, Aarthi, Hall, Michael N., Jacob, Wright, Jodrell, Duncan I., Karim, Saadia A., Klimstra, David S., Lewis, Brian C., Mizukami, Yusuke, Morton, Jennifer P., Quattrochi, Brian J., Sano, Makoto, Sansom, Owen J., Yu, Jun   +17 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

The role of adjuvant chemotherapy for patients with resected pancreatic cancer: Systematic review of randomized controlled trials and meta-analysis [PDF]

, 2007
Background: In patients undergoing surgery for resectable pancreatic cancer prognosis still remains poor. The role of adjuvant treatment strategies (including chemotherapy and chemoradiotherapy) following resection of pancreatic cancer remains ...
Bakkevold KE, Berger AC, Blackstock AW, Cress RD, Donna Pauler Ankerst, Gastrointestinal Tumour Study Group, Hochster HS, Kalser MH, Khanna A, Knaebel HP, Kosuge T, Luttges J, Oettle H, Ozols RF, Peto R, Regine WF, Stefan Boeck, Volker Heinemann   +17 more
core   +1 more source

Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti‐PD‐L1 Efficacy in Intrahepatic Cholangiocarcinoma

Advanced Science, EarlyView.
The m6A reader YTHDF1 drives intrahepatic cholangiocarcinoma (ICC) progression by remodeling the tumor immune microenvironment. YTHDF1 promotes MDSC recruitment via activation of m6A‐FOSL2‐CXCL6/CXCR2 axis, thereby suppressing CD8+ T cell infiltration and function.
Li Luo, Ziqin Liu, Zimin Song, Dong Zhang, Cong Liang, Fei Fang, Kai Lei, Lina Wang, Weikang Chen, Shunli Shen, Ming Kuang, Xiaoxing Li, Jun Yu, Shiyan Wang, Lixia Xu   +14 more
wiley   +1 more source

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

International Journal of Nanomedicine, 2019
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of ...
Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M   +7 more
doaj  

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. [PDF]

, 2017
Precision cancer medicine seeks to target the underlying genetic alterations of cancer; however, it has been challenging to use genetic profiles of individual patients in identifying the most appropriate anti-cancer drugs. This spurred the development of
Dall'Era, Marc A, de Vere White, Ralph W, Gheibi, Pantea, Ma, Ai-Hong, Pan, Chong-Xian, Revzin, Alexander, Son, Kyung Jin, Vu, Tam, Yap, Stanley Alexander, Zeng, Shuxiong   +9 more
core   +2 more sources

Liquid Metal Nanotransformers for Drug‐Resistant Pan‐Cancer Therapy in Patient‐Derived Organoids

Advanced Science, EarlyView.
Pan‐cancer therapies are severely limited in drug‐resistance patients due to genetic mutations and other factors, resulting in poor therapeutic outcomes and constrained clinical benefit. Liquid metal nanotransformers, a new class of shape‐transformable nanomaterials capable of dramatic morphological changes, offer a promising physical strategy to ...
Xiaojie Yuan, Xuelin Wang, Zhongyao Chen, Shuo Wang, Weining Gao, Ziyi Chen, Runyang Li, Cheng Hao, Lei Zhang, Qiongqiong Zhang, Ke Zhang, Mei Yu, Qian Liu, Jingxuan Wang, Huiping Li, Simpkins Fiona, Jing Liu, Qiang Liu, Peng Liu, Yawei Hu   +19 more
wiley   +1 more source

Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine

Molecules, 2017
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. Since stroma cells are developed around tumors, chemotherapeutic agents have to go through stroma cells in order to reach tumors.
Yasuhiro Tsume, Adam J. Drelich, David E. Smith, Gordon L. Amidon   +3 more
doaj   +1 more source

Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer [PDF]

, 2019
Matrix metalloproteinase 9 (MMP9) is involved in the proteolysis of extracellular proteins and plays a critical role in pancreatic ductal adenocarcinoma (PDAC) progression, invasion and metastasis.
Awasthi, Niranjan, Mikels‐Vigdal, Amanda J., Monahan, Sheena, Schwarz, Margaret A., Schwarz, Roderich E., Smith, Victoria, Stefanutti, Erin   +6 more
core   +1 more source

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source